Ameritas Advisory Services LLC Buys New Shares in Solventum Corporation $SOLV

Ameritas Advisory Services LLC bought a new stake in shares of Solventum Corporation (NYSE:SOLV) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 790 shares of the company’s stock, valued at approximately $60,000.

A number of other hedge funds also recently made changes to their positions in the business. HighMark Wealth Management LLC raised its stake in shares of Solventum by 8.7% in the 2nd quarter. HighMark Wealth Management LLC now owns 2,349 shares of the company’s stock valued at $178,000 after buying an additional 188 shares in the last quarter. SOA Wealth Advisors LLC. raised its stake in shares of Solventum by 1,397.3% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 554 shares of the company’s stock valued at $42,000 after buying an additional 517 shares in the last quarter. Chelsea Counsel Co. grew its holdings in shares of Solventum by 720.7% in the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after purchasing an additional 9,304 shares during the last quarter. HB Wealth Management LLC grew its holdings in shares of Solventum by 5.6% in the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock worth $263,000 after purchasing an additional 185 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Solventum by 1.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 37,696 shares of the company’s stock worth $2,859,000 after purchasing an additional 452 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SOLV shares. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. UBS Group started coverage on shares of Solventum in a report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 target price on the stock. Jefferies Financial Group started coverage on shares of Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $84.89.

Solventum Stock Down 1.8%

Shares of NYSE SOLV opened at $70.53 on Monday. The firm has a market capitalization of $12.23 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.87 and a beta of 0.50. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The firm’s 50-day moving average is $72.75 and its 200-day moving average is $72.08.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.